Abstract
Amongst the most promising chemopreventive agents, certain natural polyphenols have recently received a great deal of attention from the scientific community, nutritionists, the pharmaceutical industry and the public, due to their demonstrated inhibitory activity against tumorigenesis. In view of their anticancer properties, these compounds also hold great promise as potential chemotherapeutic agents. However, to translate these chemopreventive agents into chemotherapeutic compounds, their exact mechanism of action must be delineated. The aim of this manuscript is to review recent findings suggesting that certain natural products bind and antagonize the anti-apoptotic effects of Bcl-2 family proteins such as Bcl-xL and Bcl-2. We will summarize recent studies that were aimed at the identification of the molecular targets of natural polyphenols and at the characterization of their mechanism of action on a molecular level. We will emphasize the importance of these findings that resides not only in the opportunity for the development of novel cancer treatments with these compounds, but also in the structural information that can be used for the design and development of novel and more effective semi-synthetic analogues. The finding reviewed here should encourage the study of possible direct effects of other dietary compounds on Bcl-2 family proteins.
Keywords: apoptosis, bcl-2, bcl-xl, polyphenols, gossypol, apogossypol, purpurogallin, catechins, theaflavins, chemoprevention
Current Pharmaceutical Design
Title: Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Volume: 10 Issue: 12
Author(s): Maurizio Pellecchia and John C. Reed
Affiliation:
Keywords: apoptosis, bcl-2, bcl-xl, polyphenols, gossypol, apogossypol, purpurogallin, catechins, theaflavins, chemoprevention
Abstract: Amongst the most promising chemopreventive agents, certain natural polyphenols have recently received a great deal of attention from the scientific community, nutritionists, the pharmaceutical industry and the public, due to their demonstrated inhibitory activity against tumorigenesis. In view of their anticancer properties, these compounds also hold great promise as potential chemotherapeutic agents. However, to translate these chemopreventive agents into chemotherapeutic compounds, their exact mechanism of action must be delineated. The aim of this manuscript is to review recent findings suggesting that certain natural products bind and antagonize the anti-apoptotic effects of Bcl-2 family proteins such as Bcl-xL and Bcl-2. We will summarize recent studies that were aimed at the identification of the molecular targets of natural polyphenols and at the characterization of their mechanism of action on a molecular level. We will emphasize the importance of these findings that resides not only in the opportunity for the development of novel cancer treatments with these compounds, but also in the structural information that can be used for the design and development of novel and more effective semi-synthetic analogues. The finding reviewed here should encourage the study of possible direct effects of other dietary compounds on Bcl-2 family proteins.
Export Options
About this article
Cite this article as:
Pellecchia Maurizio and Reed C. John, Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384880
DOI https://dx.doi.org/10.2174/1381612043384880 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Cellular Signaling in Cartilage Tissue Engineering
Current Signal Transduction Therapy Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Diquaternized Curarelike Myorelaxants: Structure and Biological Activity
Mini-Reviews in Medicinal Chemistry Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging